acetylcysteine has been researched along with 2019 Novel Coronavirus Disease in 44 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 44 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Balansky, R; DE Flora, S; LA Maestra, S | 2 |
| Bagher Tabei, SM; Rafiee, B | 1 |
| Corsico, AG; Di Marco, F; Foti, G | 1 |
| Albuquerque, GR; Carlos, RSA; Clarindo, FA; Coelho Dos Reis, JGA; da Conceição, AO; da Mata, CPDSM; da Silva, MF; de Carvalho, LD; de Lemos, APML; de Melo Oliveira, P; Dias, JCT; Dos Santos, UR; Fehlberg, HF; Ferreira, FB; Ferreira, GM; Ferreira, LL; Filho, HPP; Fontana, R; Gadelha, SR; Goulart, GAC; Gross, E; Lopes, ATS; Lourenço, AA; Maciel, BM; Mariano, APM; Marin, LJ; Marques, DPA; Martins Filho, OA; Morris, DL; Oliveira, NRR; Quadros, CA; Rezende, RP; Ribeiro, ÁL; Romano, CC; Santana, ÍTS; Santiago, MG; Silva, MM; Sodré, MMD; Valle, SJ | 1 |
| Attalla, M; Chen, B; Daniel, N; Kang, S; Patel, M; Patel, R; Philips, M; Pierre-Louis, F; Raja, K | 1 |
| Adir, Y; Alyan, M; Arber Raviv, S; Dor, E; Egorov, E; Farkash, S; Flikshtain, OD; Gal, Y; Harush, MY; Kaneti, G; Korach-Rechtman, H; Koren, L; Mekies, LN; Nudelman, I; Pieters, C; Saadya, A; Schroeder, A; Shainsky, J; Shklover, J; Zano, A | 1 |
| Kitura, OY; Korpan, AS; Motorna, NM; Nastroga, TV; Potyazhenko, MM; Sokolyuk, NL | 1 |
| Avula, K; Behera, P; Das, SK; Kumari, S; Mohapatra, A; Mohapatra, AP; Parida, D; Senapati, S; Suresh, V; Syed, GH | 1 |
| Coronel, P; Domenech, M; Gimeno, M; Llamosí, M; Sempere, J; Yuste, J | 1 |
| Dear, JW | 1 |
| Atkin, SL; Ghanei, M; Panahi, Y; Rahimi, M; Sahebkar, A; Samim, A; Vahedian-Azimi, A | 1 |
| Alba-García, JR; Bayarri, MA; Cortijo, J; Martínez-Expósito, F; Milara, J; Montero, P; Oishi-Konari, MN; Ribera, P; Roger, I; Zapater, E | 1 |
| Kantanis, A; Karalis, I; Karamouzos, V; Koniari, I; Michailides, C; Paraskevas, T; Pierrakos, C; Velissaris, D | 1 |
| Chang, CY; Chen, CH; Cheng, YF; Chiou, SH; Chu, YC; Huang, CY; Hung, KF; Leong, JL; Wang, ML | 1 |
| Baratashvili, N; Gvaramia, L; Kandelaki, M; Samsonia, M | 1 |
| Akhter, J; Mekkawy, AH; Morris, DL; Pillai, K | 1 |
| Lee, WL; Wang, PH; Yang, ST | 1 |
| Capossela, L; Chiaretti, A; Curatola, A; Ferretti, S; Gatto, A; Graglia, B; Pansini, V | 1 |
| Abdelmottaleb, W; Ahmed, F; Al-Khazraji, Y; Fernando, QM; Iqbal, P; Jamshaid, MB; Karki, P; Madani, K; Mirza Fawad, A; Nawaz, S | 1 |
| Alfonso García Guerra, J; Arias Arias, Á; Bellido Maldonado, A; Fernández Visier, I; Galindo-Andúgar, MA; Manuel Fernández Ibáñez, J | 1 |
| Atefi, N; Baghestani, A; Goodarzi, A; Khodabandehloo, N; Mahdi, Z; Najar Nobari, N; Riahi, T; Seirafianpour, F; Talebi Taher, M; Valizadeh, R | 1 |
| Canseco, K; Goodnough, R | 2 |
| Elgamasy, S; Ghozy, S; Islam, SMS; Kamel, MG; Khalil, A; Morra, ME | 1 |
| Andreou, A; Filippou, D; Sipsas, N; Trantza, S; Tsiodras, S | 1 |
| Corn, J; Poe, FL | 1 |
| Wu, J | 1 |
| Jorge-Aarón, RM; Rosa-Ester, MP | 1 |
| Goldenberg, R; Ibrahim, H; Kon, Z; Lewis, T; Perl, A; Smith, D; Staniloae, C; Williams, M; Yarta, K | 1 |
| Becker, C; Benoliel, JJ; Elbim, C; Frère, C; Hémadi, M; Laforge, M; Massaad, C; Nuss, P | 1 |
| Raftery, MJ; Samstag, Y; Schönrich, G | 1 |
| Alamdari, AH; Alamdari, DH; Amini, S; Banpour, H; Damsaz, M; Keramati, MR; Koliakos, G; Moghaddam, AB; Yarahmadi, A; Zarmehri, AM | 1 |
| Wong, A | 1 |
| Chen, B; Leung, EL; Liu, Y; Luo, G; Qian, X; Tang, Y; Wang, M; Wu, C; Zhang, Y | 1 |
| Bhattacharyya, S; Fossum, C; Hati, S; Johnson, B; Laatsch, B; Liebau, J; Lowater, H; McCracken, C; Narkiewicz-Jodko, A; Severson, N; Suhail, S; Zajac, J | 1 |
| Li, J; Liu, D; Liu, Y; Luo, P | 1 |
| Li, SQ; Zou, H | 1 |
| Abdulle, AE; Bourgonje, AR; Hillebrands, JL; Offringa, AK; van der Voort, PHJ; van Eijk, LE; van Goor, H; van Hezik, EJ | 1 |
| Chukhliaev, PV; Garbuzov, AA; Khavkina, DA; Ploskireva, AA; Ruzhentsova, TA | 1 |
| Akhter, J; Badar, S; Frobert, E; Kepenekian, V; Mekkawy, AH; Morris, DL; Pillai, K; Quéromès, G; Valle, SJ | 1 |
| Das, S; Meher, BR; Mohanty, RR; Padhy, BM | 1 |
| Benčina, M; Bergant, V; Govednik, T; Grass, V; Hafner-Bratkovič, I; Jazbec, V; Jerala, R; Lainšček, D; Manček-Keber, M; Orehek, S; Pichlmair, A; Plaper, T | 1 |
| Avdeev, SN; Berikkhanov, ZG; Gaynitdinova, VV; Merzhoeva, ZM | 1 |
12 review(s) available for acetylcysteine and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Topics: Acetylcysteine; Antioxidants; COVID-19; Glutathione; Humans; Oxidants; Oxidative Stress; Reactive Oxygen Species; SARS-CoV-2 | 2021 |
Where are we with the use of N-acetylcysteine as a preventive and adjuvant treatment for COVID-19?
Topics: Acetylcysteine; Antioxidants; COVID-19; COVID-19 Drug Treatment; Glutathione; Humans; Oxidative Stress; Randomized Controlled Trials as Topic; Reactive Oxygen Species; SARS-CoV-2; Virus Diseases | 2022 |
N-acetylcysteine efficacy in patients hospitalized with COVID-19 pneumonia: a systematic review and meta-analysis.
Topics: Acetylcysteine; COVID-19; Hospitalization; Humans; SARS-CoV-2 | 2023 |
Is N -acetylcysteine effective in treating patients with coronavirus disease 2019? A meta-analysis.
Topics: Acetylcysteine; COVID-19; Humans; Length of Stay; SARS-CoV-2 | 2023 |
COVID-19: The Potential Role of Copper and N-acetylcysteine (NAC) in a Combination of Candidate Antiviral Treatments Against SARS-CoV-2.
Topics: Acetylcysteine; Adenosine Monophosphate; Adjuvants, Immunologic; Alanine; Anti-Inflammatory Agents; Antiviral Agents; Autophagy; Betacoronavirus; Colchicine; Copper; Coronavirus Infections; COVID-19; Cytidine; Drug Synergism; Drug Therapy, Combination; Humans; Hydroxylamines; Inflammation; Nitric Oxide; Pandemics; Pneumonia, Viral; Prodrugs; Ribonucleosides; SARS-CoV-2; Virus Internalization; Virus Replication | 2020 |
Tackle the free radicals damage in COVID-19.
Topics: Acetylcysteine; Animals; Antioxidants; Ascorbic Acid; Azithromycin; Betacoronavirus; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrome; Drug Therapy, Combination; Free Radicals; Glutathione; Humans; Hydroxychloroquine; Mice; Multiple Organ Failure; NF-E2-Related Factor 2; Nitric Oxide; Orthomyxoviridae Infections; Oxidative Stress; Pandemics; Pneumonia, Viral; Reactive Oxygen Species; SARS-CoV-2; Severe Acute Respiratory Syndrome | 2020 |
Devilishly radical NETwork in COVID-19: Oxidative stress, neutrophil extracellular traps (NETs), and T cell suppression.
Topics: Acetylcysteine; Antioxidants; Ascorbic Acid; Betacoronavirus; Coronavirus Infections; COVID-19; Cytokines; Extracellular Traps; Host-Pathogen Interactions; Humans; Immunity, Innate; Lymphopenia; Neutrophils; NF-kappa B; Oxidative Stress; Pandemics; Pneumonia, Viral; Reactive Oxygen Species; SARS-CoV-2; T-Lymphocytes | 2020 |
Rationale for the use of N-acetylcysteine in both prevention and adjuvant therapy of COVID-19.
Topics: Acetylcysteine; Angiotensin-Converting Enzyme 2; Antioxidants; Chemotherapy, Adjuvant; COVID-19; COVID-19 Drug Treatment; Humans; Oxidative Stress; SARS-CoV-2; Virus Internalization | 2020 |
Role of Oxidative Stress on SARS-CoV (SARS) and SARS-CoV-2 (COVID-19) Infection: A Review.
Topics: Acetylcysteine; Angiotensin-Converting Enzyme 2; Animals; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Discovery; Humans; Models, Molecular; Oxidative Stress; SARS-CoV-2; Severe Acute Respiratory Syndrome; Severe acute respiratory syndrome-related coronavirus; Spike Glycoprotein, Coronavirus; Viral Envelope Proteins | 2020 |
Perspectives for the Use of N-acetylcysteine as a Candidate Drug to Treat COVID-19.
Topics: Acetylcysteine; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Design; Drug Repositioning; Humans; Nitric Oxide; Reactive Oxygen Species; SARS-CoV-2 | 2021 |
N-Acetylcysteine and Hydrogen Sulfide in Coronavirus Disease 2019.
Topics: Acetylcysteine; COVID-19; Humans; Hydrogen Sulfide; Oxidation-Reduction | 2021 |
Therapeutic potential of N-acetyl cysteine (NAC) in preventing cytokine storm in COVID-19: review of current evidence.
Topics: Acetylcysteine; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrome; Humans; Prognosis; SARS-CoV-2 | 2021 |
2 trial(s) available for acetylcysteine and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Evaluation the efficacy and safety of N-acetylcysteine inhalation spray in controlling the symptoms of patients with COVID-19: An open-label randomized controlled clinical trial.
Topics: Acetylcysteine; Administration, Inhalation; COVID-19; Humans; Length of Stay; Nebulizers and Vaporizers; Oral Sprays; SARS-CoV-2; Treatment Outcome | 2023 |
Evaluation of the efficacy and safety of oral N-acetylcysteine in patients with COVID-19 receiving the routine antiviral and hydroxychloroquine protocol: A randomized controlled clinical trial.
Topics: Acetylcysteine; Antiviral Agents; Atazanavir Sulfate; C-Reactive Protein; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Inflammation; Randomized Controlled Trials as Topic; Ritonavir; SARS-CoV-2 | 2023 |
30 other study(ies) available for acetylcysteine and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
The effect of N-acetyl cysteine consumption on men with abnormal sperm parameters due to positive history of COVID-19 in the last three months.
Topics: Acetylcysteine; COVID-19; Female; Humans; Infertility, Male; Male; SARS-CoV-2; Semen; Semen Analysis; Sperm Count; Sperm Motility; Spermatozoa | 2021 |
Ex-vivo mucolytic and anti-inflammatory activity of BromAc in tracheal aspirates from COVID-19.
Topics: Acetylcysteine; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Bromelains; Chemokines; COVID-19; Cytokine Release Syndrome; Cytokines; Dose-Response Relationship, Drug; Down-Regulation; Drug Combinations; Expectorants; Female; Humans; Inflammation Mediators; Male; Middle Aged; Respiration, Artificial; Rheology; SARS-CoV-2; Sputum; Trachea; Young Adult | 2022 |
Intravenous N-Acetylcysteine in Management of COVID-19: A Case Series.
Topics: Acetylcysteine; COVID-19; Cytokine Release Syndrome; Glutathione; Glutathione Reductase; Humans; NF-kappa B; Retrospective Studies; SARS-CoV-2 | 2023 |
Lung targeted liposomes for treating ARDS.
Topics: Acetylcysteine; Animals; COVID-19; Humans; Inflammation; Lipopolysaccharides; Liposomes; Lung; Lung Diseases; Mice; Mice, Inbred C57BL; Nanoparticles; Respiratory Distress Syndrome; Tumor Necrosis Factor-alpha | 2022 |
EFFICIENT COMPREHENSIVE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE EXACERBATION AND POSTCOVIDAL SYNDROME IN ELDERLY PATIENTS.
Topics: Acetylcysteine; Aged; COVID-19; COVID-19 Drug Treatment; Glycine; Humans; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quality of Life; Sodium Chloride | 2022 |
Therapeutic role of N-acetyl cysteine (NAC) for the treatment and/or management of SARS-CoV-2-induced lung damage in hamster model.
Topics: Acetylcysteine; Animals; COVID-19; Cricetinae; Interleukin-6; Lung; Reactive Oxygen Species; SARS-CoV-2 | 2023 |
Combination of Cefditoren and
Topics: Acetylcysteine; Animals; Anti-Bacterial Agents; Antioxidants; Biofilms; Cephalosporins; COVID-19; Humans; Mice; Respiratory Tract Infections; SARS-CoV-2; Streptococcus pneumoniae | 2022 |
Fomepizole should not be used more liberally in paracetamol overdose.
Topics: Acetaminophen; Acetylcysteine; Analgesics, Non-Narcotic; Chemical and Drug Induced Liver Injury; COVID-19; Drug Overdose; Fomepizole; Humans | 2023 |
N-acetylcysteine Reduces Inflammasome Activation Induced by SARS-CoV-2 Proteins In Vitro.
Topics: Acetylcysteine; COVID-19; Cytokines; Humans; Inflammasomes; NLR Family, Pyrin Domain-Containing 3 Protein; Recombinant Proteins; SARS-CoV-2 | 2022 |
NEUROPROTECTIVE AND ANTIOXIDANT POTENTIAL OF MONTELUKAST-ACETYLCYSTEINE COMBINATION THERAPY FOR BRAIN PROTECTION IN PATIENTS WITH COVID-19 INDUCED PNEUMONIA.
Topics: Acetylcysteine; Adult; Aged; Antioxidants; COVID-19; Diabetes Mellitus, Type 2; Humans; Interleukin-6; Microcirculation; Middle Aged; Oxygen; Pneumonia, Viral; Respiratory Distress Syndrome; SARS-CoV-2 | 2023 |
Effect of Nebulized BromAc on Rheology of Artificial Sputum: Relevance to Muco-Obstructive Respiratory Diseases.
Topics: Acetylcysteine; Bromelains; COVID-19; Expectorants; Humans; Respiration Disorders; Rheology; Sputum | 2023 |
Effectiveness of N-acetylcysteine in treating patients with coronavirus disease 2019 may be in doubt but in uncertainty.
Topics: Acetylcysteine; COVID-19; Humans; Treatment Outcome; Uncertainty | 2023 |
Early treatment with N-acetylcysteine reduces hepatotoxicity in acute acetaminophen poisoning.
Topics: Acetaminophen; Acetylcysteine; Adolescent; Adult; Chemical and Drug Induced Liver Injury; Child; COVID-19; Digestive System Diseases; Drug Overdose; Female; Humans | 2023 |
Asymptomatic COVID-19 presenting with features of mixed pattern acute liver injury in a young healthy female, a case report.
Topics: Acetylcysteine; COVID-19; Female; Humans; Liver | 2023 |
Impact of N-Acetylcysteine in the mortality of patients hospitalized with COVID-19: a retrospective cohort study.
Topics: Acetylcysteine; Aged; Aged, 80 and over; Cohort Studies; COVID-19; Female; Humans; Male; Middle Aged; Retrospective Studies; SARS-CoV-2 | 2023 |
Truncated IV acetylcysteine treatment duration has potential to safely preserve resources during the COVID-19 pandemic.
Topics: Acetaminophen; Acetylcysteine; COVID-19; Duration of Therapy; Humans; Pandemics; SARS-CoV-2 | 2021 |
First case of focal epilepsy associated with SARS-coronavirus-2.
Topics: Acetaminophen; Acetylcysteine; Aged; Ambroxol; Anticonvulsants; Cough; COVID-19; COVID-19 Drug Treatment; Dipyrone; Epilepsies, Partial; Female; Fever; Humans; Nasopharynx; Radiography, Abdominal; SARS-CoV-2; Treatment Outcome | 2020 |
N-Acetylcysteine: A potential therapeutic agent for SARS-CoV-2.
Topics: Acetylcysteine; Betacoronavirus; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Free Radicals; Glutathione; Humans; Inflammation; NLR Family, Pyrin Domain-Containing 3 Protein; Oxidation-Reduction; Oxidative Stress; Pandemics; Pneumonia, Viral; SARS-CoV-2; Severe Acute Respiratory Syndrome; T-Lymphocytes; Tumor Necrosis Factor-alpha; Viral Load | 2020 |
N-acetylcysteine as a potential treatment for COVID-19.
Topics: Acetylcysteine; Angiotensin II; Antioxidants; Betacoronavirus; Coronavirus Infections; COVID-19; Cytokines; Humans; Oxidative Stress; Pandemics; Pneumonia, Viral; SARS-CoV-2; Virus Internalization | 2020 |
Therapeutic blockade of inflammation in severe COVID-19 infection with intravenous N-acetylcysteine.
Topics: Acetylcysteine; Adult; Antioxidants; Antirheumatic Agents; Betacoronavirus; Biomarkers; C-Reactive Protein; Coronavirus Infections; COVID-19; Cytokine Release Syndrome; Drug Administration Schedule; Ferritins; Fibrin Fibrinogen Degradation Products; Glucosephosphate Dehydrogenase Deficiency; Humans; Hydroxychloroquine; Inflammation; Male; Pandemics; Pneumonia, Viral; SARS-CoV-2; Treatment Outcome | 2020 |
Tissue damage from neutrophil-induced oxidative stress in COVID-19.
Topics: Acetylcysteine; Antioxidants; Betacoronavirus; Coronavirus Infections; COVID-19; Cytokines; Drug Therapy, Combination; Extracellular Traps; Gene Expression Regulation; Glycine; Host-Pathogen Interactions; Humans; Immunity, Innate; Lung; Lymphocytes; Neutrophils; NF-E2-Related Factor 2; NF-kappa B; Oxidative Stress; Pandemics; Pneumonia, Viral; Proteinase Inhibitory Proteins, Secretory; Reactive Oxygen Species; SARS-CoV-2; Severity of Illness Index; Sulfonamides; Superoxide Dismutase | 2020 |
Application of methylene blue -vitamin C -N-acetyl cysteine for treatment of critically ill COVID-19 patients, report of a phase-I clinical trial.
Topics: Acetylcysteine; Ascorbic Acid; Clinical Trials, Phase I as Topic; Compassionate Use Trials; Coronavirus Infections; COVID-19; Critical Illness; Female; Humans; Hypoxia; Male; Methylene Blue; Middle Aged; Pandemics; Pneumonia, Viral | 2020 |
Comment on Truncated IV acetylcysteine treatment duration has potential to safely preserve resources during the COVID-19 pandemic.
Topics: Acetylcysteine; COVID-19; Duration of Therapy; Humans; Pandemics; SARS-CoV-2 | 2021 |
Response to Comment on Truncated IV acetylcysteine treatment duration has potential to safely preserve resources during the COVID-19 pandemic.
Topics: Acetylcysteine; COVID-19; Duration of Therapy; Humans; Pandemics; SARS-CoV-2 | 2021 |
Experience of N-acetylcysteine airway management in the successful treatment of one case of critical condition with COVID-19: A case report.
Topics: Acetylcysteine; Administration, Inhalation; Airway Management; Anastomosis, Surgical; Betacoronavirus; Bronchoalveolar Lavage; Coronavirus Infections; COVID-19; Humans; Intubation, Intratracheal; Length of Stay; Male; Middle Aged; Pandemics; Pneumonia, Viral; Pneumothorax; Respiration, Artificial; SARS-CoV-2 | 2020 |
Pulmonary fibrosis in critically ill patients with novel coronavirus pneumonia during the convalescent stage and a proposal for early intervention.
Topics: Acetylcysteine; Convalescence; COVID-19; COVID-19 Drug Treatment; Early Medical Intervention; Glucocorticoids; Humans; Indoles; Pulmonary Fibrosis; Pyridones; SARS-CoV-2 | 2021 |
[Effect of anticoagulant therapy on the course of COVID-19 in comorbid patients].
Topics: Acetylcysteine; Aged; Aged, 80 and over; Anticoagulants; Antiviral Agents; Atrial Fibrillation; Azithromycin; Cohort Studies; Comorbidity; Coronary Disease; COVID-19; COVID-19 Drug Treatment; Dabigatran; Disseminated Intravascular Coagulation; Female; Humans; Hypertension; Indoles; Interferon alpha-2; Intracranial Arteriosclerosis; Male; Middle Aged; Pyrazoles; Pyridones; Rivaroxaban; SARS-CoV-2; Severity of Illness Index; Survival Analysis | 2021 |
The Combination of Bromelain and Acetylcysteine (BromAc) Synergistically Inactivates SARS-CoV-2.
Topics: Acetylcysteine; Antiviral Agents; Bromelains; COVID-19; COVID-19 Drug Treatment; Drug Evaluation, Preclinical; Drug Synergism; Humans; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Virus Inactivation | 2021 |
Disruption of disulfides within RBD of SARS-CoV-2 spike protein prevents fusion and represents a target for viral entry inhibition by registered drugs.
Topics: Acetylcysteine; Amides; Ascorbic Acid; Auranofin; COVID-19; COVID-19 Drug Treatment; Disulfides; Esters; HEK293 Cells; Humans; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Sulfhydryl Compounds; Virus Internalization | 2021 |
N-acetylcysteine for the treatment of COVID-19 among hospitalized patients.
Topics: Acetylcysteine; COVID-19; Humans; Hydrogen Sulfide; SARS-CoV-2 | 2022 |